Insys Therapeutics (NASDAQ: INSY) reported Q4 EPS of $0.03, $0.03 better than the analyst estimate of $0.00. Revenue for the quarter came in at $54.9 million versus the consensus estimate of $51.15 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.